Resolution Therapeutics, an Edinburgh, Scotland, and London, UK-based clinical-stage biopharmaceutical company, raised £63.5M in Series B funding.
The round was led by Syncona Ltd. Alongside the financing, Resolution also announced the appointment of Paul Sekhri, a seasoned life sciences executive with decades of drug development and extensive business development experience, as Chair of the Board of Directors.
The company intends to use the funds to advance its lead candidate, RTX001, an autologous, engineered, pro-regenerative macrophage cell therapy specifically designed to deliver transformative outcomes in patients with end-stage liver disease.
Led by CEO Amir Hefni, Resolution Therapeutics is a clinical-stage biopharmaceutical company focused on improving the regenerative potential of macrophage therapy for the treatment of inflammatory and fibrotic diseases. It leverages its proprietary cell characterisation and engineering platform to develop autologous macrophages with distinct pro-regenerative properties for superior patient outcomes across the spectrum of inflammatory and fibrotic diseases.
Its initial focus is on developing RTX001, its lead product candidate with first-in-class potential supported by preclinical data demonstrating anti-fibrotic and anti-inflammatory advantages relative to non-engineered macrophages, for patients diagnosed with end-stage liver disease. The company is also advancing efforts to expand the potential of its platform into indications beyond liver disease where engineered macrophages have therapeutic potential.
FinSMEs
03/10/2024